Trial Profile
Study for the effect of blood glucose and metabolic risk factors by switching Sulfonylurea to SGLT2 inhibitor in patients with type 2 diabetes. -prospective observational study-
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 May 2020
Price :
$35
*
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- 05 Jun 2018 Status changed from active, no longer recruiting to completed.
- 22 Feb 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 29 Jan 2015 New trial record